Decoy Therapeutics (NASDAQ:DCOY) Sees Significant Decline in Short Interest

Decoy Therapeutics (NASDAQ:DCOY) was the target of a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 23,986 shares, a drop of 84.7% from the June 30th total of 156,313 shares. Approximately 4.6% of the company’s shares are short sold. Based on an average trading volume of 44,863 shares, the short-interest ratio is currently 0.5 days.

Decoy Therapeutics Price Performance

Shares of DCOY stock traded up $0.10 during trading hours on Friday, reaching $5.04. The company’s stock had a trading volume of 9,632 shares, compared to its average volume of 683,977. Decoy Therapeutics has a one year low of $4.32 and a one year high of $415.80. The company has a market capitalization of $2.67 million, a PE ratio of -0.05 and a beta of 0.59. The business’s fifty day moving average is $6.44.

Decoy Therapeutics (NASDAQ:DCOY) last announced its earnings results on Friday, May 8th. The company reported ($4.18) EPS for the quarter. Analysts expect that Decoy Therapeutics will post -12.97 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, June 12th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.